{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:27:25Z","timestamp":1773275245041,"version":"3.50.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,7]],"date-time":"2016-10-07T00:00:00Z","timestamp":1475798400000},"content-version":"vor","delay-in-days":372,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1038\/mt.2015.125","type":"journal-article","created":{"date-parts":[[2015,7,9]],"date-time":"2015-07-09T11:20:54Z","timestamp":1436440854000},"page":"1641-1652","source":"Crossref","is-referenced-by-count":25,"title":["Biodistribution Analysis of Oncolytic Adenoviruses in Patient Autopsy Samples Reveals Vascular Transduction of Noninjected Tumors and Tissues"],"prefix":"10.1016","volume":"23","author":[{"given":"Anniina","family":"Koski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simona","family":"Bramante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anja","family":"Kipar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minna","family":"Oksanen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juuso","family":"Juhila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lotta","family":"Vassilev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timo","family":"Joensuu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Kanerva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akseli","family":"Hemminki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1038\/mt.2015.125_bib1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.18_suppl.lba9008","article-title":"OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB\/C and IV melanoma","volume":"31","author":"Andtbacka","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1038\/mt.2015.125_bib2","first-page":"1666","article-title":"[Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus]","volume":"23","author":"Xia","year":"2004","journal-title":"Ai Zheng"},{"key":"10.1038\/mt.2015.125_bib3","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/cgt.2011.7","article-title":"Clinical development directions in oncolytic viral therapy","volume":"18","author":"Eager","year":"2011","journal-title":"Cancer Gene Ther"},{"key":"10.1038\/mt.2015.125_bib4","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2174\/156800907780058817","article-title":"Clinical trials with oncolytic adenovirus in China","volume":"7","author":"Yu","year":"2007","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1038\/mt.2015.125_bib5","doi-asserted-by":"crossref","first-page":"e28694","DOI":"10.4161\/onci.28694","article-title":"Trial Watch: Oncolytic viruses for cancer therapy","volume":"3","author":"Pol","year":"2014","journal-title":"Oncoimmunology"},{"key":"10.1038\/mt.2015.125_bib6","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.ygyno.2013.06.003","article-title":"A phase I clinical trial of Ad5\/3-\u039424, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer","volume":"130","author":"Kim","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1038\/mt.2015.125_bib7","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ijrobp.2014.02.034","article-title":"Prospective randomized phase 2 trial of intensity modulated radiation therapy with or without oncolytic adenovirus-mediated cytotoxic gene therapy in intermediate-risk prostate cancer","volume":"89","author":"Freytag","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1038\/mt.2015.125_bib8","first-page":"693","article-title":"Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies","volume":"9","author":"Makower","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1038\/mt.2015.125_bib9","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/mt.2009.262","article-title":"A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors","volume":"18","author":"Nemunaitis","year":"2010","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2015.125_bib10","doi-asserted-by":"crossref","first-page":"676","DOI":"10.4161\/cbt.8.8.7913","article-title":"A Phase I study of KH901, a conditionally replicating granulocyte-macrophage colony-stimulating factor: armed oncolytic adenovirus for the treatment of head and neck cancers","volume":"8","author":"Chang","year":"2009","journal-title":"Cancer Biol Ther"},{"key":"10.1038\/mt.2015.125_bib11","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.cytogfr.2010.02.002","article-title":"GM-CSF-armed, replication-competent viruses for cancer","volume":"21","author":"Burke","year":"2010","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1038\/mt.2015.125_bib12","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1016\/j.juro.2012.07.097","article-title":"A first in human phase 1 study of CG0070, a GM-CSF expressing oncolytic adenovirus, for the treatment of nonmuscle invasive bladder cancer","volume":"188","author":"Burke","year":"2012","journal-title":"J Urol"},{"key":"10.1038\/mt.2015.125_bib13","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/B978-0-12-398342-8.00008-2","article-title":"Chapter eight\u2013Oncolytic adenoviruses for cancer immunotherapy: data from mice, hamsters, and humans","volume":"115","author":"Cerullo","year":"2012","journal-title":"Adv Cancer Res"},{"key":"10.1038\/mt.2015.125_bib14","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1158\/1078-0432.CCR-11-2852","article-title":"A phase I clinical trial of Ad5.SSTR\/TK.RGD, a novel infectivity-enhanced bicistronic adenovirus, in patients with recurrent gynecologic cancer","volume":"18","author":"Kim","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1038\/mt.2015.125_bib15","first-page":"33","article-title":"Persistent replication of the modified chimeric adenovirus ONYX-015 in both tumor and stromal cells from a patient with gall bladder carcinoma implants","volume":"9","author":"Wadler","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1038\/mt.2015.125_bib16","article-title":"T cell subsets in peripheral blood and tumors of patients treated with oncolytic adenoviruses","author":"Taipale","year":"2015","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2015.125_bib17","doi-asserted-by":"crossref","first-page":"4467","DOI":"10.18632\/oncotarget.2901","article-title":"Immunological data from cancer patients treated with Ad5\/3-E2F-\u039424-GMCSF suggests utility for tumor immunotherapy","volume":"6","author":"Hemminki","year":"2015","journal-title":"Oncotarget"},{"key":"10.1038\/mt.2015.125_bib18","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1038\/mt.2010.161","article-title":"Treatment of cancer patients with a serotype 5\/3 chimeric oncolytic adenovirus expressing GMCSF","volume":"18","author":"Koski","year":"2010","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2015.125_bib19","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3109\/07853890.2010.538079","article-title":"In vivo and in vitro distribution of type 5 and fiber-modified oncolytic adenoviruses in human blood compartments","volume":"43","author":"Escutenaire","year":"2011","journal-title":"Ann Med"},{"key":"10.1038\/mt.2015.125_bib20","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1002\/ijc.26216","article-title":"Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors","volume":"130","author":"Pesonen","year":"2012","journal-title":"Int J Cancer"},{"key":"10.1038\/mt.2015.125_bib21","doi-asserted-by":"crossref","first-page":"5763","DOI":"10.1200\/JCO.2009.24.3675","article-title":"Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma","volume":"27","author":"Senzer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1038\/mt.2015.125_bib22","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1002\/ijc.28615","article-title":"In vivo magnetic resonance imaging and spectroscopy identifies oncolytic adenovirus responders","volume":"134","author":"Hemminki","year":"2014","journal-title":"Int J Cancer"},{"key":"10.1038\/mt.2015.125_bib23","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1089\/hum.2013.123","article-title":"[(18)F]-fluorodeoxyglucose positron emission tomography and computed tomography in response evaluation of oncolytic adenovirus treatments of patients with advanced cancer","volume":"24","author":"Koski","year":"2013","journal-title":"Hum Gene Ther"},{"key":"10.1038\/mt.2015.125_bib24","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/sj.cgt.7700819","article-title":"Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU\/leucovorin","volume":"12","author":"Reid","year":"2005","journal-title":"Cancer Gene Ther"},{"key":"10.1038\/mt.2015.125_bib25","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1158\/1078-0432.CCR-12-2546","article-title":"Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus","volume":"19","author":"Kanerva","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1038\/mt.2015.125_bib26","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1136\/bmjspcare-2013-000621","article-title":"Diagnosing dying: an integrative literature review","volume":"4","author":"Kennedy","year":"2014","journal-title":"BMJ Support Palliat Care"},{"key":"10.1038\/mt.2015.125_bib27","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1634\/theoncologist.2013-0457","article-title":"Clinical signs of impending death in cancer patients","volume":"19","author":"Hui","year":"2014","journal-title":"Oncologist"},{"key":"10.1038\/mt.2015.125_bib28","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1001\/jamainternmed.2014.1001","article-title":"Use of chemotherapy within the last 14 days of life in patients treated at a comprehensive cancer center","volume":"174","author":"Rodriguez","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.1038\/mt.2015.125_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jpainsymman.2012.07.007","article-title":"Targeted agent use in cancer patients at the end of life","volume":"46","author":"Hui","year":"2013","journal-title":"J Pain Symptom Manage"},{"key":"10.1038\/mt.2015.125_bib30","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2174\/156652307780859062","article-title":"Current advances and future challenges in Adenoviral vector biology and targeting","volume":"7","author":"Campos","year":"2007","journal-title":"Curr Gene Ther"},{"key":"10.1038\/mt.2015.125_bib31","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1158\/1078-0432.CCR-09-3167","article-title":"Oncolytic adenovirus ICOVIR-7 in patients with advanced and refractory solid tumors","volume":"16","author":"Nokisalmi","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1038\/mt.2015.125_bib32","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1158\/0008-5472.CAN-11-3001","article-title":"Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients","volume":"72","author":"Pesonen","year":"2012","journal-title":"Cancer Res"},{"key":"10.1038\/mt.2015.125_bib33","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1038\/gt.2010.17","article-title":"Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5\/3-Cox2L-D24 in patients with metastatic and refractory solid tumors","volume":"17","author":"Pesonen","year":"2010","journal-title":"Gene Ther"},{"key":"10.1038\/mt.2015.125_bib34","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.1158\/0008-5472.CAN-09-3567","article-title":"Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients","volume":"70","author":"Cerullo","year":"2010","journal-title":"Cancer Res"},{"key":"10.1038\/mt.2015.125_bib35","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1089\/hum.2014.001","article-title":"Innate immunity to adenovirus","volume":"25","author":"Hendrickx","year":"2014","journal-title":"Hum Gene Ther"},{"key":"10.1038\/mt.2015.125_bib36","doi-asserted-by":"crossref","first-page":"7686","DOI":"10.1038\/sj.onc.1209063","article-title":"Inactivating intracellular antiviral responses during adenovirus infection","volume":"24","author":"Weitzman","year":"2005","journal-title":"Oncogene"},{"key":"10.1038\/mt.2015.125_bib37","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1038\/mt.2012.115","article-title":"Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer","volume":"20","author":"Hemminki","year":"2012","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2015.125_bib38","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1097\/INF.0b013e3181d743c8","article-title":"Persistence of adenovirus nucleic acids in nasopharyngeal secretions: a diagnostic conundrum","volume":"29","author":"Kalu","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"10.1038\/mt.2015.125_bib39","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1128\/JVI.02392-08","article-title":"Latent species C adenoviruses in human tonsil tissues","volume":"83","author":"Garnett","year":"2009","journal-title":"J Virol"},{"key":"10.1038\/mt.2015.125_bib40","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1128\/JVI.59.1.189-192.1986","article-title":"Group C adenovirus DNA sequences in human lymphoid cells","volume":"59","author":"Horvath","year":"1986","journal-title":"J Virol"},{"key":"10.1038\/mt.2015.125_bib41","doi-asserted-by":"crossref","first-page":"7629","DOI":"10.1128\/JVI.00355-07","article-title":"Investigation of adenovirus occurrence in pediatric tumor entities","volume":"81","author":"Kosulin","year":"2007","journal-title":"J Virol"},{"key":"10.1038\/mt.2015.125_bib42","series-title":"Fields Virology","first-page":"pp. 2355","article-title":"Adenoviridae: The viruses and their replication","author":"Berk","year":"2007"},{"key":"10.1038\/mt.2015.125_bib43","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/sj.gt.3302387","article-title":"Noninvasive dual modality in vivo monitoring of the persistence and potency of a tumor targeted conditionally replicating adenovirus","volume":"12","author":"Kanerva","year":"2005","journal-title":"Gene Ther"},{"key":"10.1038\/mt.2015.125_bib44","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/gt.2011.176","article-title":"Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4","volume":"19","author":"Dias","year":"2012","journal-title":"Gene Ther"},{"key":"10.1038\/mt.2015.125_bib45","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/ijc.28696","article-title":"Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans","volume":"135","author":"Bramante","year":"2014","journal-title":"Int J Cancer"},{"key":"10.1038\/mt.2015.125_bib46","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1038\/mt.2012.170","article-title":"Treatment of chemotherapy-refractory cancer in the advanced therapy access program","volume":"20","author":"Hemminki","year":"2012","journal-title":"Mol Ther"},{"key":"10.1038\/mt.2015.125_bib47","first-page":"862925","article-title":"Oncolytic immunotherapy: where are we clinically?","volume":"2014","author":"Hemminki","year":"2014","journal-title":"Scientifica (Cairo)"},{"key":"10.1038\/mt.2015.125_bib48","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1354\/vp.42-3-321","article-title":"Morphologic features and development of granulomatous vasculitis in feline infectious peritonitis","volume":"42","author":"Kipar","year":"2005","journal-title":"Vet Pathol"},{"key":"10.1038\/mt.2015.125_bib49","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S1525-0016(03)00200-4","article-title":"Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus","volume":"8","author":"Kanerva","year":"2003","journal-title":"Mol Ther"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001616302957?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001616302957?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T21:03:27Z","timestamp":1599253407000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001616302957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":49,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S1525001616302957"],"URL":"https:\/\/doi.org\/10.1038\/mt.2015.125","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]}}}